Literature DB >> 33369885

Quantitative assessment of p16 expression in FNA specimens from head and neck squamous cell carcinoma and correlation with HPV status.

Rita Abi-Raad1, Manju L Prasad1, Syed Gilani1, James Garritano2,3, Deborah Barlow1, Guoping Cai1, Adebowale J Adeniran1.   

Abstract

BACKGROUND: This study investigated p16 by immunohistochemistry (IHC) on cellblocks (CBs) and human papillomavirus (HPV) by polymerase chain reaction (PCR) in fine-needle aspiration (FNA) of head and neck squamous cell carcinoma (HNSCC).
METHODS: Receiver operating characteristic (ROC) curve analysis was used to assess test performance in CBs compared with p16 IHC in 42 surgical specimens from patients with HNSCC and in correlation with HPV by PCR in cytology specimens. The study assessed HPV by PCR in FNA specimens as a substitute for p16 IHC in surgical specimens.
RESULTS: Of 42 cases, 38 CBs showed malignant cells as cohesive clusters of viable cells with or without single tumor cells, whereas 4 specimens were composed exclusively of single tumor cells and degenerated cells. All p16-negative surgical specimens showed an absence of p16 staining in the corresponding CBs (n = 16). In the p16-positive surgical cases (n = 26), corresponding CBs with tumor clusters (n = 23) showed heterogeneous p16 expression ranging from 40% to 100%; however, scoring single cells was challenging and unreliable because of cellular degradation. ROC curve inspection showed the optimal threshold to be at least 40% p16 staining in tumor clusters with 100% sensitivity and specificity. In cases with inadequate CBs, HPV by PCR on needle rinse showed 88% sensitivity and 100% specificity for p16 expression in surgical specimens.
CONCLUSIONS: A cutoff of at least 40% p16 expression in tumor clusters may be appropriate for p16 positivity in cytology CB specimens. A positive HPV finding by PCR on needle rinse can be used as a substitute for p16 expression in surgical specimens.
© 2020 American Cancer Society.

Entities:  

Keywords:  fine-needle aspiration; head and neck squamous cell carcinoma; human papillomavirus; p16

Mesh:

Substances:

Year:  2020        PMID: 33369885      PMCID: PMC8875293          DOI: 10.1002/cncy.22399

Source DB:  PubMed          Journal:  Cancer Cytopathol        ISSN: 1934-662X            Impact factor:   5.284


  39 in total

Review 1.  HPV-associated head and neck cancer: a virus-related cancer epidemic.

Authors:  Shanthi Marur; Gypsyamber D'Souza; William H Westra; Arlene A Forastiere
Journal:  Lancet Oncol       Date:  2010-05-05       Impact factor: 41.316

2.  The utility of p16 immunostaining in fine needle aspiration in p16-positive head and neck squamous cell carcinoma.

Authors:  Bin Xu; Ronald Ghossein; Jason Lane; Oscar Lin; Nora Katabi
Journal:  Hum Pathol       Date:  2016-04-19       Impact factor: 3.466

3.  p16 expression as a surrogate marker for HPV-related oropharyngeal carcinoma: a guide for interpretative relevance and consistency.

Authors:  Adel K El-Naggar; William H Westra
Journal:  Head Neck       Date:  2011-12-16       Impact factor: 3.147

4.  Is immunohistochemical evaluation of p16 in oropharyngeal cancer enough to predict the HPV positivity?

Authors:  Paweł Golusiński; Jakub Pazdrowski; Mateusz Szewczyk; Maciej Misiołek; Wioletta Pietruszewska; Janusz Klatka; Sławomir Okła; Henryk Kaźmierczak; Andrzej Marszałek; Violetta Filas; Augusto Schneider; Michał M Masternak; Katarzyna Stęplewska; Katarzyna Miśkiewicz-Orczyk; Wojciech Golusiński
Journal:  Rep Pract Oncol Radiother       Date:  2017-04-22

5.  Detection of human papillomavirus-16 in fine-needle aspirates to determine tumor origin in patients with metastatic squamous cell carcinoma of the head and neck.

Authors:  Shahnaz Begum; Maura L Gillison; Theresa L Nicol; William H Westra
Journal:  Clin Cancer Res       Date:  2007-02-15       Impact factor: 12.531

6.  The Fidelity of p16 Staining as a Surrogate Marker of Human Papillomavirus Status in Fine-Needle Aspirates and Core Biopsies of Neck Node Metastases: Implications for HPV Testing Protocols.

Authors:  Brittany J Holmes; Zahra Maleki; William H Westra
Journal:  Acta Cytol       Date:  2015-03-10       Impact factor: 2.319

7.  Correlation of p16 immunohistochemistry in FNA biopsies with corresponding tissue specimens in HPV-related squamous cell carcinomas of the oropharynx.

Authors:  Jalal B Jalaly; James S Lewis; Brian T Collins; Xingyong Wu; Xiao-Jun Ma; Yuling Luo; Cory T Bernadt
Journal:  Cancer Cytopathol       Date:  2015-08-04       Impact factor: 5.284

8.  Heterogeneity of p16 immunohistochemistry and increased sensitivity of RNA in situ hybridization in cytology specimens of HPV-related head and neck squamous cell carcinoma.

Authors:  Kristine S Wong; Jeffrey F Krane; Vickie Y Jo
Journal:  Cancer Cytopathol       Date:  2019-09-11       Impact factor: 5.284

9.  Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers.

Authors:  Anil K Chaturvedi; William F Anderson; Joannie Lortet-Tieulent; Maria Paula Curado; Jacques Ferlay; Silvia Franceschi; Philip S Rosenberg; Freddie Bray; Maura L Gillison
Journal:  J Clin Oncol       Date:  2013-11-18       Impact factor: 44.544

10.  pROC: an open-source package for R and S+ to analyze and compare ROC curves.

Authors:  Xavier Robin; Natacha Turck; Alexandre Hainard; Natalia Tiberti; Frédérique Lisacek; Jean-Charles Sanchez; Markus Müller
Journal:  BMC Bioinformatics       Date:  2011-03-17       Impact factor: 3.307

View more
  2 in total

1.  Detection of Human Papillomavirus in Squamous Lesions of the Conjunctiva Using RNA and DNA In-Situ Hybridization.

Authors:  Cornelia Peterson; Rupin N Parikh; Meleha T Ahmad; Ashley A Campbell; Yassine Daoud; Nicholas Mahoney; Sepideh Siadati; Charles G Eberhart
Journal:  Int J Mol Sci       Date:  2022-06-29       Impact factor: 6.208

2.  Detection accuracy of the Cobas HPV assay for high-risk HPV in head and neck FNA biopsy specimens.

Authors:  Ming Guo; Abha Khanna; Agata A Tinnirello; Jessica Hwang; Ping Zhang; Li Xu; Guojun Li; Kristina R Dahlstrom; Erich M Sturgis; John Stewart
Journal:  Cancer Cytopathol       Date:  2022-02-22       Impact factor: 4.264

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.